New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:50 EDTISISIsis Pharmaceuticals price target raised to $51 from $43 at BMO Capital
BMO Capital raised its price target on Isis as the firm expects the company to report favorable data for its ISIS-SMN-Rx treatment. The firm also expects interest in the company's other antisense oligonucleotide programs for neurodegenerative conditions to increase. It keeps an Outperform rating on the shares.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
14:30 EDTISISIsis Pharmaceuticals to hold an investor event
Management hosts an investor event to discuss the ISIS-SMN Rx data presented at the 2014 American Academy of Neurology's Annual Meeting in Philadelphia on April 29 at 6 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use